Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Viveve Medical (VIVE)

Viveve Medical (VIVE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,586
  • Shares Outstanding, K 10,592
  • Annual Sales, $ 5,480 K
  • Annual Income, $ -21,920 K
  • 60-Month Beta 0.65
  • Price/Sales 4.60
  • Price/Cash Flow N/A
  • Price/Book 1.06
Trade VIVE with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -2.60
  • Growth Rate Est. (year over year) +38,523.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.25 +8.44%
on 09/22/21
3.08 -20.78%
on 09/20/21
-0.03 (-1.21%)
since 08/24/21
3-Month
2.25 +8.44%
on 09/22/21
3.22 -24.22%
on 06/29/21
-0.26 (-9.63%)
since 06/24/21
52-Week
2.25 +8.44%
on 09/22/21
6.78 -63.99%
on 11/23/20
-2.64 (-51.96%)
since 09/24/20

Most Recent Stories

More News
Viveve Announces Issuance of New Method Patent for Stress Urinary Incontinence in Australia

Patent strengthens and expands Viveve's intellectual property portfolio for the treatment of stress urinary incontinence

VIVE : 2.44 (-2.79%)
Viveve to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

ENGLEWOOD, CO / ACCESSWIRE / September 7, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive...

VIVE : 2.44 (-2.79%)
Viveve Reports Second Quarter 2021 Financial Results and Provides Corporate Update

VIVE : 2.44 (-2.79%)
Viveve to Host Conference Call on August 12, 2021 to Report Second Quarter Financial Results and Provide Corporate Update

ENGLEWOOD, CO / ACCESSWIRE / August 5, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its second quarter...

VIVE : 2.44 (-2.79%)
Viveve Announces Continued Expansion of IP Portfolio with Issuance of Canadian Patent

ENGLEWOOD, CO / ACCESSWIRE / August 3, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that the Canadian Intellectual Property...

VIVE : 2.44 (-2.79%)
Viveve Announces New Category III CPT Code for its Stress Urinary Incontinence Procedure

New code approved by American Medical Association and supported by key medical societies

VIVE : 2.44 (-2.79%)
Viveve to Participate in Ladenburg Thalmann Healthcare Virtual Conference

ENGLEWOOD, CO / ACCESSWIRE / July 6, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer,...

VIVE : 2.44 (-2.79%)
Viveve Announces Issuance of New Device and Methods Patent in U.S.

ENGLEWOOD, CO / ACCESSWIRE / June 10, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that the United States Patent and Trademark...

VIVE : 2.44 (-2.79%)
Viveve Announces Adjournment of Annual Meeting

Meeting scheduled to reconvene June 23, 2021 at 12:00 PM Eastern TimeCompany encourages stockholders to cast their votes

VIVE : 2.44 (-2.79%)
Viveve Reports First Quarter 2021 Financial Results and Provides Corporate Update

VIVE : 2.44 (-2.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Viveve Medical, Inc. is a medical device company focused on technologies for the cardiac and vascular markets. The Company's lead product, RenalGuard (R), is designed to remove contrast dyes that are known to be toxic to the kidneys. Viveve Medical Inc., formerly known as PLC Systems Inc., is headquartered...

See More

Key Turning Points

3rd Resistance Point 2.72
2nd Resistance Point 2.61
1st Resistance Point 2.53
Last Price 2.44
1st Support Level 2.34
2nd Support Level 2.23
3rd Support Level 2.15

See More

52-Week High 6.78
Fibonacci 61.8% 5.05
Fibonacci 50% 4.51
Fibonacci 38.2% 3.98
Last Price 2.44
52-Week Low 2.25

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar